Key result
Circulating ACE2 activity was significantly decreased in patients with CKD stages 3-5 and on dialysis compared to controls, and correlated with older age, diabetes, and male gender.
Why the study?
How does circulating ACE2 activity change in patients with chronic kidney disease without a history of cardiovascular disease compared to controls?
Population
2,572 patients without a history of cardiovascular disease from the NEFRONA study, including a control…
Design
Cohort
Authors
Loading...
ACE2 activity elevation in non-CV CKD patients warrants CV risk monitoring; hypothesis-generating for ACE2-targeted interventions in CKD.
Observational (n=2,572)
How does circulating ACE2 activity change in patients with chronic kidney disease without a history of cardiovascular disease compared to controls?
Circulating ACE2 activity is decreased in CKD patients without prior cardiovascular disease and correlates with classical cardiovascular risk factors such as older age, diabetes, and male gender.
Anguiano et al. (2015) conducted an observational in Chronic kidney disease without previous history of cardiovascular disease (n=2,572). Chronic kidney disease (stages 3-5 and dialysis) vs. Control group was evaluated on Circulating ACE2 activity. Circulating ACE2 activity was significantly decreased in patients with CKD stages 3-5 and on dialysis compared to controls, and correlated with older age, diabetes, and male gender.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: